OrbiMed, a healthcare-focused venture capital firm, has closed its fifth royalty and credit opportunities fund at $1.86 billion to provide businesses with financing alternatives as equity capital becomes more costly.

The New York-based healthcare investor beat its $1.75 billion goal for OrbiMed Royalty and Credit Opportunities Fund V. The fund, which closed on Fri